TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 21490978

Group type: EXPERIMENTAL
Intervention: Rapid maxillary expansion (RME) and face mask therapy
Number of subjects: 33

Group type: COMPARATOR
Intervention: Control group (untreated Class III subjects)
Number of subjects: 33
Study: 17272491

Group type: EXPERIMENTAL
Intervention: alpha-tocopherol (500 mg/day)
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: mixed tocopherols (500 mg/day)
Number of subjects: 55

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 55
Study: 15655442

Group type: EXPERIMENTAL
Intervention: Comfort care (swaddled, held, and given 24% sucrose solution)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control (examined while lying in their cribs)
Number of subjects: 30
Study: 12142596

Group type: EXPERIMENTAL
Intervention: Vacuum-Assisted Closure (VAC)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Healthpoint System (HP)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: VAC
Number of subjects: 28

Group type: COMPARATOR
Intervention: HP
Number of subjects: 28
Study: 9932843

Group type: EXPERIMENTAL
Intervention: Sacrosidase
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Sacrosidase plus milk
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Higher concentrations of sacrosidase
Number of subjects: 28

Group type: COMPARATOR
Intervention: Lower concentrations of sacrosidase
Number of subjects: 28

Group type: COMPARATOR
Intervention: Baseline period (no sacrosidase)
Number of subjects: 28
Study: 7800307

Group type: EXPERIMENTAL
Intervention: Dehydroepiandrosterone sulfate (DHAS) 200 mg intravenous in 20 mL of 5% dextrose
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control group (20 mL of 5% dextrose)
Number of subjects: 10
Study: 2347955

Group type: EXPERIMENTAL
Intervention: Ceftibuten 200 mg taken orally twice daily (7:00 AM and 7:00 PM) during the trial period.
Number of subjects: 12

Group type: COMPARATOR
Intervention: Theophylline (4 mg/kg) administered intravenously without ceftibuten treatment.
Number of subjects: 12
Study: 659922

Group type: EXPERIMENTAL
Intervention: 1.0 ml intramuscularly (im) administered human diploid cell rabies virus vaccine
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: 0.1 ml intradermally (id) administered human diploid cell rabies virus vaccine
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Booster dose of vaccine administered by subcutaneous or id route
Number of subjects: 77
Study: 31804433

Group type: EXPERIMENTAL
Intervention: Online educational program for oncology nurses
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Changes in recruitment strategies (adding incentives, shortening surveys, increasing reminders)
Number of subjects: 0
Study: 31634441

Group type: EXPERIMENTAL
Intervention: Kangaroo Position (KP)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 44
Study: 27164220

Group type: EXPERIMENTAL
Intervention: 200 mg Theacrine (TeaCrine®)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: 400 mg Theacrine (TeaCrine®)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo (PLA)
Number of subjects: 24
Study: 25179314

Group type: EXPERIMENTAL
Intervention: Ivabradine
Number of subjects: 43

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 43
Study: 22972745

Group type: EXPERIMENTAL
Intervention: TCZ 4 mg/kg + DMARDs
Number of subjects: 886

Group type: EXPERIMENTAL
Intervention: TCZ 8 mg/kg + DMARDs
Number of subjects: 886

Group type: EXPERIMENTAL
Intervention: TCZ 8 mg/kg monotherapy
Number of subjects: 886

Group type: EXPERIMENTAL
Intervention: Overall
Number of subjects: 886
Study: 20478003

Group type: EXPERIMENTAL
Intervention: Nurse follow-up
Number of subjects: 110

Group type: COMPARATOR
Intervention: Surgeon follow-up
Number of subjects: 110
Study: 19767814

Group type: EXPERIMENTAL
Intervention: Carbohydrate-protein mixture (9% sucrose solution + 3% whey protein isolate, 0.4 g.kg‐1 body mass.h‐1)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Carbohydrate alone (9% sucrose solution, 1.2 g.kg‐1 body mass.h‐1)
Number of subjects: 17
Study: 17582067

Group type: EXPERIMENTAL
Intervention: Paromomycin (11 mg/kg intramuscularly daily for 21 days)
Number of subjects: 667

Group type: COMPARATOR
Intervention: Amphotericin B (1 mg/kg intravenously every other day for 30 days)
Number of subjects: 667

Group type: EXPERIMENTAL
Intervention: Paromomycin
Number of subjects: 667

Group type: COMPARATOR
Intervention: Amphotericin B
Number of subjects: 667
Study: 15363822

Group type: EXPERIMENTAL
Intervention: Amlodipine besylate/benazapril (force titrated to 5/40 mg)
Number of subjects: 6300

Group type: COMPARATOR
Intervention: Benazapril/hydrochlorothiazide (force titrated to 40/12.5 mg)
Number of subjects: 6300
Study: 11765671

Group type: EXPERIMENTAL
Intervention: Safety committee regulations
Number of subjects: 3286

Group type: EXPERIMENTAL
Intervention: Safety program regulations
Number of subjects: 3286

Group type: EXPERIMENTAL
Intervention: Insurance carrier loss control regulations
Number of subjects: 3286

Group type: EXPERIMENTAL
Intervention: Targeting initiatives
Number of subjects: 3286
Study: 9551418

Group type: EXPERIMENTAL
Intervention: Bicarbonate (38 mM) solution
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Bicarbonate (25 mM)/lactate (15 mM) solution
Number of subjects: 18

Group type: COMPARATOR
Intervention: Control lactate (40 mM) solution
Number of subjects: 18
Study: 7846213

Group type: EXPERIMENTAL
Intervention: Caffeine (200 + 50 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 3214495

Group type: EXPERIMENTAL
Intervention: Lomefloxacin 100 mg
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Lomefloxacin 200 mg
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Lomefloxacin 400 mg
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Lomefloxacin 600 mg
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Lomefloxacin 800 mg
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 30870203

Group type: EXPERIMENTAL
Intervention: Mirtazapine (30 mg)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Zolpidem (sustained-release 12.5 mg)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Mirtazapine (30 mg IR) plus zolpidem (10 mg)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 29035169

Group type: EXPERIMENTAL
Intervention: Psychoeducation intervention for patients preparing for HCV treatment
Number of subjects: 154

Group type: EXPERIMENTAL
Intervention: Consistent abstinence from alcohol, drugs, and smoking
Number of subjects: 154

Group type: EXPERIMENTAL
Intervention: Consistent use of alcohol, drugs, and smoking
Number of subjects: 154

Group type: EXPERIMENTAL
Intervention: Achievement of abstinence after study entry for alcohol, drugs, and smoking
Number of subjects: 154
Study: 27495186

Group type: EXPERIMENTAL
Intervention: $5 gift card incentive
Number of subjects: 152

Group type: COMPARATOR
Intervention: No monetary incentive
Number of subjects: 152
Study: 25698120

Group type: EXPERIMENTAL
Intervention: Need-based nutritional intervention (50 g/day soy-protein-based nutritional supplement)
Number of subjects: 92

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 92
Study: 23578528

Group type: EXPERIMENTAL
Intervention: Newhints intervention
Number of subjects: 16329

Group type: COMPARATOR
Intervention: Control intervention
Number of subjects: 16329
Study: 20806678

Group type: EXPERIMENTAL
Intervention: Mailed educational materials
Number of subjects: 170

Group type: EXPERIMENTAL
Intervention: Interactive seminars
Number of subjects: 170

Group type: COMPARATOR
Intervention: Both educational strategies
Number of subjects: 170
Study: 19139000

Group type: EXPERIMENTAL
Intervention: Chromoendoscopy
Number of subjects: 50

Group type: COMPARATOR
Intervention: Intensive inspection (standard colonoscopy)
Number of subjects: 50
Study: 16206100

Group type: EXPERIMENTAL
Intervention: Iron sulfate combined with a 2-week course of lansoprazole, clarithromycin, and amoxicillin
Number of subjects: 219

Group type: COMPARATOR
Intervention: Iron sulfate alone
Number of subjects: 219

Group type: EXPERIMENTAL
Intervention: Metronidazole-based quadruple therapy (re-treatment)
Number of subjects: 219
Study: 12800480

Group type: EXPERIMENTAL
Intervention: Intensive insulin therapy (insulin infusion tailored to control blood glucose levels in the range 80-110 mg/dL)
Number of subjects: 1548

Group type: EXPERIMENTAL
Intervention: Intensive insulin therapy
Number of subjects: 1548
Study: 10235612

Group type: EXPERIMENTAL
Intervention: Interferon retreatment at original dose (group A1: 234 MU, 11 patients; group B1: 468 MU, 10 patients)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Interferon retreatment at twice the original dose (group A2: 468 MU, 11 patients; group B2: 936 MU, 10 patients)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: All treatment groups
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Complete sustained responders
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Increasing the dose of interferon above that of the first cycle
Number of subjects: 42
Study: 8729100

Group type: EXPERIMENTAL
Intervention: Vitamin E supplementation (100 IU/d for 3 months)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 35
Study: 1898811

Group type: EXPERIMENTAL
Intervention: iohexol 180 mg l/ml
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: iohexol 300 mg l/ml
Number of subjects: 64

Group type: COMPARATOR
Intervention: barium
Number of subjects: 64
Study: 6549746

Group type: EXPERIMENTAL
Intervention: pH-sensitive enteric coated pancreatic enzyme preparation
Number of subjects: 6

Group type: COMPARATOR
Intervention: Conventional pancreatic enzyme preparation
Number of subjects: 6
Study: 30979342

Group type: EXPERIMENTAL
Intervention: Rural households
Number of subjects: 376

Group type: COMPARATOR
Intervention: Urban households
Number of subjects: 376
Study: 29300292

Group type: EXPERIMENTAL
Intervention: Structured verbal instruction plus a leaflet
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Structured verbal instruction
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Leaflet alone
Number of subjects: 60

Group type: COMPARATOR
Intervention: Usual care (unstructured verbal counseling)
Number of subjects: 60
Study: 26979765

Group type: EXPERIMENTAL
Intervention: Minimally Invasive Unicondylar Knee Arthroplasty (MUKA)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Minimally Invasive Total Knee Arthroplasty (TKA)
Number of subjects: 32
Study: 25074878

Group type: EXPERIMENTAL
Intervention: Standard adjuvant chemotherapy
Number of subjects: 329

Group type: COMPARATOR
Intervention: Capecitabine
Number of subjects: 329

Group type: EXPERIMENTAL
Intervention: Comorbidity burden score
Number of subjects: 329

Group type: EXPERIMENTAL
Intervention: Overall survival (OS)
Number of subjects: 329
Study: 22230921

Group type: EXPERIMENTAL
Intervention: Acute oral SAL (6 mg)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Short-term oral SAL (12 mg day(‐1) for 3 weeks)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo (gelatin)
Number of subjects: 8
Study: 20845112

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Stress Management plus Expressive Supportive Therapy (CBSM+)
Number of subjects: 451

Group type: COMPARATOR
Intervention: Individual informational intervention
Number of subjects: 451
Study: 17643995

Group type: EXPERIMENTAL
Intervention: Intravenous paracetamol (1 g) administered 15 min before the end of surgery and every 6h for 72 h
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: Intravenous paracetamol (1 g)
Number of subjects: 113

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 113
Study: 17101319

Group type: EXPERIMENTAL
Intervention: Synthetic human ghrelin (0.33 mug/kg)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 38
Study: 12794781

Group type: COMPARATOR
Intervention: Rofecoxib
Number of subjects: 60

Group type: COMPARATOR
Intervention: Celecoxib
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Rofecoxib and Celecoxib
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Proton-pump inhibitors with COX-2 NSAIDs
Number of subjects: 60
Study: 11056128

Group type: EXPERIMENTAL
Intervention: Triptorelin acetate 15 microg daily
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Triptorelin acetate 50 microg daily
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Triptorelin acetate 100 microg daily
Number of subjects: 240

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 240
Study: 9366786

Group type: EXPERIMENTAL
Intervention: Graded-exercise test (G-test)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Constant-load test (C-test)
Number of subjects: 52
Study: 1328579

Group type: EXPERIMENTAL
Intervention: Commercial milk formula containing 1% bovine milk immunoglobulin concentrate from hyperimmunized cows
Number of subjects: 232

Group type: COMPARATOR
Intervention: Commercial milk formula (control)
Number of subjects: 232
Study: 2412793

Group type: EXPERIMENTAL
Intervention: Low frequency sinusoidal whole body vibration (0.3 m/sec2, rms)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Low frequency random whole body vibration (0.3 m/sec2, rms)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Pauses without exposure to vibration
Number of subjects: 30
Study: 31421157

Group type: EXPERIMENTAL
Intervention: SIRT + sorafenib
Number of subjects: 424

Group type: COMPARATOR
Intervention: sorafenib alone
Number of subjects: 424

Group type: EXPERIMENTAL
Intervention: SIRT + sorafenib (per protocol population)
Number of subjects: 424

Group type: COMPARATOR
Intervention: sorafenib alone (per protocol population)
Number of subjects: 424

Group type: EXPERIMENTAL
Intervention: SIRT + sorafenib (subgroup without cirrhosis)
Number of subjects: 424

Group type: EXPERIMENTAL
Intervention: SIRT + sorafenib (subgroup cirrhosis of non-alcoholic aetiology)
Number of subjects: 424

Group type: EXPERIMENTAL
Intervention: SIRT + sorafenib (subgroup patients ≤65 years old)
Number of subjects: 424

Group type: COMPARATOR
Intervention: SIRT only
Number of subjects: 424
Study: 30586005

Group type: EXPERIMENTAL
Intervention: TX-001HR (1/100 mg)
Number of subjects: 1994

Group type: EXPERIMENTAL
Intervention: TX-001HR (0.5/100 mg)
Number of subjects: 1994

Group type: EXPERIMENTAL
Intervention: TX-001HR (0.5/50 mg)
Number of subjects: 1994

Group type: EXPERIMENTAL
Intervention: TX-001HR (0.25/50 mg)
Number of subjects: 1994

Group type: EXPERIMENTAL
Intervention: TX-001HR (all doses)
Number of subjects: 1994

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1994
Study: 26859081

Group type: EXPERIMENTAL
Intervention: High-dose cytarabine and mitoxantrone (HAM)
Number of subjects: 3375

Group type: COMPARATOR
Intervention: Standard-dose cytarabine, daunorubicin and 6-thioguanine (TAD)
Number of subjects: 3375

Group type: EXPERIMENTAL
Intervention: Granulocyte-colony stimulating factor (G-CSF)
Number of subjects: 3375

Group type: COMPARATOR
Intervention: No G-CSF
Number of subjects: 3375

Group type: EXPERIMENTAL
Intervention: Autotransplant
Number of subjects: 3375

Group type: COMPARATOR
Intervention: Maintenance chemotherapy
Number of subjects: 3375
Study: 24534204

Group type: EXPERIMENTAL
Intervention: QVA149 110/50 μg
Number of subjects: 85

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 85

Group type: COMPARATOR
Intervention: Tiotropium 18 μg
Number of subjects: 85
Study: 22469638

Group type: EXPERIMENTAL
Intervention: Fentanyl (1.5 µg/kg)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Buprenorphine (1.5 µg/kg)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Combination of fentanyl (0.75 µg/kg) and buprenorphine (0.75 µg/kg)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Saline (0.9%)
Number of subjects: 15
Study: 20681275

Group type: EXPERIMENTAL
Intervention: Shexiang Baoxin Pill (SXBXP) administered at 2 pills, three times a day for at least 6 months, in addition to conventional therapy.
Number of subjects: 200

Group type: COMPARATOR
Intervention: Conventional therapy (anti-platelet, blood lipid regulating, anti-ischemia) without SXBXP.
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Shexiang Baoxin Pill (SXBXP)
Number of subjects: 200
Study: 17928942

Group type: EXPERIMENTAL
Intervention: Active Hyperthermia (AH)
Number of subjects: 6
Study: 16046473

Group type: EXPERIMENTAL
Intervention: Maximal Resistance Exercise (MRE) during LTBR
Number of subjects: 12

Group type: COMPARATOR
Intervention: Long-term bedrest (LTBR) without exercise
Number of subjects: 12
Study: 12455714

Group type: EXPERIMENTAL
Intervention: Angiotensin converting enzyme inhibitors (ACEI) for four weeks
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo (after two week wash out period)
Number of subjects: 32
Study: 10600428

Group type: EXPERIMENTAL
Intervention: Computerized feedback system
Number of subjects: 19
Study: 8530573

Group type: EXPERIMENTAL
Intervention: leuprolide depot (3.75 mg/month) plus conjugated estrogen (0.625 mg/day) and medroxyprogesterone acetate (10 mg; days 1‐12)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Oral contraceptive pills (OCP) containing ethynodiol diacetate (1 mg) and ethinyl estradiol (35 micrograms)
Number of subjects: 17
Study: 2009436

Group type: EXPERIMENTAL
Intervention: Hypnotherapy
Number of subjects: 0
Study: 6351529

Group type: EXPERIMENTAL
Intervention: Tiapride
Number of subjects: 13
Study: 31036106

Group type: EXPERIMENTAL
Intervention: Nerve excision group (ilioinguinal neurectomy)
Number of subjects: 180

Group type: COMPARATOR
Intervention: Nerve preservation group
Number of subjects: 180
Study: 30037514

Group type: EXPERIMENTAL
Intervention: 30 mL/kg of intravenous Lactated Ringer's solution (LR)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Normal saline (NS)
Number of subjects: 30
Study: 26690555

Group type: EXPERIMENTAL
Intervention: Acetaminophen (APAP; 1 g every 6 hours for seven days)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study: 24612987

Group type: EXPERIMENTAL
Intervention: Norfloxacin (400 mg daily)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Trimethoprim-sulfamethoxazole (160/800 mg daily)
Number of subjects: 80
Study: 22065252

Group type: EXPERIMENTAL
Intervention: Modular treatment (62 youths)
Number of subjects: 174

Group type: COMPARATOR
Intervention: Standard manual treatment (59 youths)
Number of subjects: 174

Group type: COMPARATOR
Intervention: Usual care (53 youths)
Number of subjects: 174
Study: 19397178

Group type: EXPERIMENTAL
Intervention: RightStart program
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not in RightStart program (Control)
Number of subjects: 0
Study: 17488375

Group type: EXPERIMENTAL
Intervention: Early cyclosporine microemulsion (CsA‐ME, day 0)
Number of subjects: 203

Group type: COMPARATOR
Intervention: Delayed cyclosporine microemulsion (CsA‐ME, day 6)
Number of subjects: 203

Group type: EXPERIMENTAL
Intervention: Both early and delayed CsA‐ME groups
Number of subjects: 203
Study: 16217327

Group type: EXPERIMENTAL
Intervention: Botulinum toxin B (5,000 IU diluted up to 20 ml)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo (20 ml normal saline)
Number of subjects: 20
Study: 11948071

Group type: COMPARATOR
Intervention: Placebo-controlled study for treatment of asthma
Number of subjects: 0
Study: 9585802

Group type: COMPARATOR
Intervention: Eprosartan 350 mg
Number of subjects: 31

Group type: COMPARATOR
Intervention: Eprosartan 10 mg
Number of subjects: 31

Group type: COMPARATOR
Intervention: Eprosartan 30 mg
Number of subjects: 31

Group type: COMPARATOR
Intervention: Eprosartan 50 mg
Number of subjects: 31

Group type: COMPARATOR
Intervention: Eprosartan 70 mg
Number of subjects: 31

Group type: COMPARATOR
Intervention: Eprosartan 100 mg
Number of subjects: 31

Group type: COMPARATOR
Intervention: Eprosartan 200 mg
Number of subjects: 31
Study: 7857995

Group type: EXPERIMENTAL
Intervention: Active experimental drug
Number of subjects: 33

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 33
Study: 2530763

Group type: EXPERIMENTAL
Intervention: Paroxetine
Number of subjects: 120

Group type: COMPARATOR
Intervention: Imipramine
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study: 1090297

Group type: EXPERIMENTAL
Intervention: Azathioprine
Number of subjects: 17
Study: 31941795

Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC), 2,700 mg/d for adults; 30 mg/kg/d for pediatrics
Number of subjects: 33

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 33
Study: 31285161

Group type: EXPERIMENTAL
Intervention: STOP-Bang questionnaire
Number of subjects: 4118
Study: 28662618

Group type: EXPERIMENTAL
Intervention: Face-to-face treatments (16 studies)
Number of subjects: 3879

Group type: COMPARATOR
Intervention: Self-guided treatments (11 studies)
Number of subjects: 3879
Study: 26593080

Group type: EXPERIMENTAL
Intervention: Oxygen saturation targeting
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 23222258

Group type: EXPERIMENTAL
Intervention: Dedicated noninvasive ventilators
Number of subjects: 24

Group type: COMPARATOR
Intervention: ICU ventilators
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Noninvasive ventilation sessions
Number of subjects: 24
Study: 20845395

Group type: EXPERIMENTAL
Intervention: Rivastigmine patch (9.5 mg/24 h)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Rivastigmine capsules (12 mg/day)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Best supportive care (BSC)
Number of subjects: 0
Study: 19334486

Group type: EXPERIMENTAL
Intervention: ronkoleukine therapy (0.1 mg submucously and 0.4 mg intravenously, 3 times with 72 hour intervals)
Number of subjects: 108

Group type: COMPARATOR
Intervention: standard therapy (proton pump inhibitor and two antibiotics: amoxicillin and clarithromycin)
Number of subjects: 108
Study: 16686568

Group type: EXPERIMENTAL
Intervention: Cold Water Immersion (CWI; 13.98 degrees C)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Ice Water Immersion (IWI; 5.23 degrees C)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Mock Treatment (MT; 29.50 degrees C)
Number of subjects: 15
Study: 15281968

Group type: EXPERIMENTAL
Intervention: Tonosafe disposable tonometer head
Number of subjects: 69

Group type: COMPARATOR
Intervention: Goldmann tonometer head
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Tonosafe disposable tonometer head (subgroup analysis for IOP > 21 mmHg)
Number of subjects: 69

Group type: COMPARATOR
Intervention: Goldmann tonometer head (subgroup analysis for IOP > 21 mmHg)
Number of subjects: 69
Study: 15530582

Group type: EXPERIMENTAL
Intervention: Breast-feeding promotion program
Number of subjects: 683

Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 683
Study: 10357114

Group type: EXPERIMENTAL
Intervention: Sodium aurothiomalate (gold therapy)
Number of subjects: 36